The Impact of Anti-Obesity Drugs on Patients and Industries

New anti-obesity drugs developed by Novo Nordisk and Eli Lilly have the potential to transform public health by reducing appetite and helping people feel fuller for longer. These drugs, known as GLP-1 drugs, have already seen soaring sales and are expected to have a significant impact on the medical, food, and fitness industries. However, their adoption remains uncertain due to high costs and harsh side effects. If widely adopted, these drugs could disrupt industries such as snacks, fast food, medical devices, weight management treatments, and addiction-related industries. While some companies may benefit from the shift in consumer spending, others may see their markets shrink.